Phathom Pharmaceuticals currently has a negative Return on Invested Capital (ROIC) of -53.45%, which is much lower than its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is common in clinical-stage biopharmaceutical companies due to heavy research and development expenses before product commercialization. Among its peers, only Arcutis Biotherapeutics shows a positive ROIC, though still below its WACC, highlighting its relatively better capital efficiency. The trend reflects the financial challenges biotech firms face in balancing innovation costs with value creation.
Tower Semiconductor announced it will publish its second quarter 2026 financial results on August 4, 2026, followed by a conference call to discuss the earnings and provide guidance for the third quarter. The call will be webcast and accessible via t...
AmpliTech Group announced a board-approved stock repurchase program allowing up to $10 million in buybacks over 24 months, signaling confidence in its record revenue and expanding order book. Concurrently, the company terminated its At-The-Market equ...
KAR Electrical Power Production Trading FZE (KEPPT) has appointed J.P. Morgan to coordinate financing for its $1.6 billion urea plant in Basra, Iraq. The plant, expected to start construction in 2027 and operation by 2030, will produce 1.15 million t...
KEPPT has appointed J.P. Morgan to arrange financing for a $1.6 billion urea plant in Basra, Iraq, aiming to reduce reliance on imports and support the agricultural sector. The plant will produce 1.15 million tonnes annually and is expected to start ...
KEPPT has appointed J.P. Morgan to arrange financing for a $1.6 billion urea plant in Basra, Iraq, set to produce 1.15 million tonnes annually. This project aims to reduce Iraq's dependence on urea imports, support the agricultural sector, and stimul...
